Compare DWSN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | BNR |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 126.5M |
| IPO Year | 1995 | 2019 |
| Metric | DWSN | BNR |
|---|---|---|
| Price | $3.15 | $16.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.6K | 49.9K |
| Earning Date | 05-12-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $145,773,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $6.79 |
| 52 Week High | $7.85 | $41.72 |
| Indicator | DWSN | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 73.89 |
| Support Level | $3.09 | $15.61 |
| Resistance Level | $3.73 | $18.59 |
| Average True Range (ATR) | 0.22 | 1.38 |
| MACD | 0.02 | 0.46 |
| Stochastic Oscillator | 22.22 | 100.00 |
Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.